Investor Presentaiton

Clinical Strategy Overview Growing Body of Clinical & Real-life Evidence BLAST OSA CE Mark BETTER SLEEP CCC label - Europe EIISA Long term data - Europe DREAM FDA approval ACCCESS CCC label US Commercial European sales N=22 BLAST OSA AHI Responder Rates N=36 BETTER SLEEP N=34 DREAM @6 months 50% @6 months 64% @ 12 months 65% 8 ~500 patients implanted and >125 doctors trained with Genio in clinical trials and commercially BETTER SLEEP led to CCC label expansion in Europe and BDD in the US - CCC patients represent 30% of OSA patients, currently contraindicated for HGNS in US Nyxoah

View entire presentation